Anika Therapeutics Stock
Anika Therapeutics Stock
Anika Therapeutics dominated the market today, gaining €1.00 (4.070%).
Currently there is a rather positive sentiment for Anika Therapeutics with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 26 € shows a slightly positive potential of 1.56% compared to the current price of 25.6 € for Anika Therapeutics.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | 4.070% | 7.563% | 6.667% | 9.402% | 25.490% | -24.260% | -17.192% |
| Ardelyx Inc. | 5.470% | 34.723% | 16.633% | 93.717% | 39.758% | 44.250% | - |
| Evolus Inc | 4.240% | 17.143% | 2.500% | 61.842% | 35.912% | 68.493% | - |
| Salarius Pharmaceuticals Inc. | -1.300% | 6.573% | 5.581% | -68.472% | -18.198% | -98.220% | -99.993% |
Comments
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target raised by analysts at Barrington Research from $28.00 to $29.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics, Inc. (NASDAQ: ANIK) had its price target raised by analysts at Barrington Research from $24.00 to $28.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics, Inc. (NASDAQ: ANIK) was upgraded by analysts at Barrington Research from a "market perform" rating to an "outperform" rating.
Show more
Ratings data for ANIK provided by MarketBeat